CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients

Clinical Pharmacology and Therapeutics

Volumn 81, Issue 2, 2007, Pages 228-234

  Renders, L ^a   Frisman, M ^a   Ufer, M ^a   Mosyagin, I ^a   Haenisch, S ^a   Ott, U ^b   Caliebe, A ^a   Dechant, M ^a   Braun, F ^a   Kunzendorf, U ^a   Cascorbi, I ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; CYTOCHROME P450 3A5; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; TACROLIMUS;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; GENOTYPE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CALCIUM CHANNEL BLOCKERS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HALF-LIFE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PREDNISOLONE; SIROLIMUS; TACROLIMUS; VARIATION (GENETICS);

EID: 33846632909     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100039     Document Type: Article

References (51)

1. Morozumi, K., Takeda, A., Uchida, K. & Mihatsch, M.J. Cyclosporine nephrotoxicity: how does it affect renal allograft function and transplant morphology? Transplant. Proc. 36, 251S-256S (2004).
2. Venkataramanan, R. et al. Clinical pharmacokinetics of tacrolimus. Clin. Pharmacokinet. 29, 404-430 (1995).
3. Yatscoff, R.W. Pharmacokinetics of rapamycin. Transplant. Proc. 28, 970-973 (1996).
4. Evans, W.E. & Relling, M.V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286, 487-491 (1999).
5. Hustert, E. et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11, 773-779 (2001).
6. Jacobsen, W., Serkova, N., Hausen, B., Morris, R.E., Benet, L.Z. & Christians, U. Comparison of the in vitro metabolism of the macrolide immunosuppressants sirolimus and RAD. Transplant. Proc. 33, 514-515 (2001).
7. Kamdem, L.K. et al. Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin. Chem. 51, 1374-1381 (2005).
8. Wallemacq, P.E. & Verbeeck, R.K. Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients. Clin. Pharmacokinet. 40, 283-295 (2001).
9. Zimmerman, J.J. & Kahan, B.D. Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. J. Clin. Pharmacol. 37, 405-415 (1997).
10. Wojnowski, L. & Kamdem, L.K. Clinical implications of CYP3A polymorphisms. Expert Opin. Drug Metab. Toxicol. 2, 171-182 (2006).
11. Westlind-Johnsson, A. et al. Identification and characterization of CYP3A4*20, a novel rare CYP3A4 allele without functional activity. Clin. Pharmacol. Ther. 79, 339-349 (2006).
12. Kuehl, P. et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27, 383-391 (2001).
13. Lampen, A., Zhang, Y., Hackbarth, I., Benet, L.Z., Sewing, K.F. & Christians, U. Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine. J. Pharmacol. Exp. Ther. 285, 1104-1112 (1998).
14. Saeki, T., Ueda, K., Tanigawara, Y., Hori, R. & Komano, T. Human P-glycoprotein transports cyclosporin A and FK506. J. Biol. Chem. 268, 6077-6080 (1993).
15. Yacyshyn, B.R., Bowen-Yacyshyn, M.B. & Pilarski, L.M. Inhibition by rapamycin of P-glycoprotein 170-mediated export from normal lymphocytes. Scand. J. Immunol. 43, 449-455 (1996).
16. Kamisako, T. et al. Transport of monoglucuronosyl and bisglucuronosyl bilirubin by recombinant human and rat multidrug resistance protein 2. Hepatology. 30, 485-490 (1999).
17. Cascorbi, I. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol. Ther. 112, 457-473 (2006).
18. Anglicheau, D. et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J. Am. Soc. Nephrol. 14, 1889-1896 (2003).
19. Haufroid, V. et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 14, 147-154 (2004).
20. Anglicheau, D. et al. Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy. Am. J. Transplant. 5, 595-603 (2005).
21. Mourad, M. et al. Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. Transplantation 80, 977-984 (2005).
22. Goto, M. et al. CYP3A5*1-carrying graft liver reduces the concentration/ oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics 14, 471-478 (2004).
23. Haufroid, V. et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 14, 147-154 (2004).
24. Thervet, E. et al. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 76, 1233-1235 (2003).
25. Zhang, X. et al. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation. Clin. Transplant. 19, 638-643 (2005).
26. Zhao, Y. et al. Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus. Transplant. Proc. 37, 178-181 (2005).
27. Le Meur, Y. et al. CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. Clin. Pharmacol. Ther. 80, 51-60 (2006).
28. Le Meur, Y. et al. CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. Clin. Pharmacol. Ther. 80, 51-60 (2006).
29. Chen, Y.L., Hirabayashi, H., Akhtar, S., Pelzer, M. & Kobayashi, M. Simultaneous determination of three isomeric metabolites of tacrolimus (FK506) in human whole blood and plasma using high performance liquid chromatography-tandem mass spectrometry. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 830, 330-341 (2006).
30. Iwasaki, K. et al. Isolation, identification, and biological activities of oxidative metabolites of FK506, a potent immunosuppressive macrolide lactone. Drug Metab. Dispos. 21, 971-977 (1993).
31. Iwasaki, K. et al. Further metabolism of FK506 (tacrolimus). Identification and biological activities of the metabolites oxidized at multiple sites of FK506. Drug Metab. Dispos. 23, 28-34 (1995).
32. Iwasaki, K. et al. Isolation, identification, and biological activities of oxidative metabolites of FK506, a potent immunosuppressive macrolide lactone. Drug Metab. Dispos. 21, 971-977 (1993).
33. Iwasaki, K. et al. Further metabolism of FK506 (tacrolimus). Identification and biological activities of the metabolites oxidized at multiple sites of FK506. Drug Metab. Dispos. 23, 28-34 (1995).
34. Renders, L., Haas, C.S., Liebelt, J., Oberbarnscheidt, M., Schocklmann, H.O. & Kunzendorf, U. Tacrolimus and cerivastatin pharmacokinetics and adverse effects after single and multiple dosing with cerivastatin in renal transplant recipients. Br. J. Clin. Pharmacol. 56, 214-219 (2003).
35. Cheung, C.Y. et al. Influence of different allelic variants of the CYP3A and ABCB1 genes on the tacrolimus pharmacokinetic profile of Chinese renal transplant recipients. Pharmacogenomics 7, 563-574 (2006).
36. Tada, H. et al. Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplant. Proc. 37, 1730-1732 (2005).
37. Kuypers, D.R. & Vanrenterghem, Y. Time to reach tacrolimus maximum blood concentration,mean residence time, and acute renal allograft rejection: an open-label, prospective, pharmacokinetic study in adult recipients. Clin. Ther. 26, 1834-1844 (2004).
38. Haufroid, V. et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 14, 147-154 (2004).
39. Hesselink, D.A. et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin. Pharmacol. Ther. 74, 245-254 (2003).
40. Hauser, I.A., Koziolek, M., Hausknecht, B. & Thevenod, F. Cyclosporin A, but not FK506, increases the expression of multidrug resistance P-glycoprotein (MDR1) in human arterial endothelial cells. J. Am. Soc. Nephrol. 8, A2805 (1997).
41. Le Meur, Y. et al. CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. Clin. Pharmacol. Ther. 80, 51-60 (2006).
42. Anglicheau, D. et al. Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy. Am. J. Transplant. 5, 595-603 (2005).
43. Mourad, M. et al. Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. Transplantation 80, 977-984 (2005).
44. Lampen, A., Zhang, Y., Hackbarth, I., Benet, L.Z., Sewing, K.F. & Christians, U. Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine. J. Pharmacol. Exp. Ther. 285, 1104-1112 (1998).
45. Sattler, M., Guengerich, F.P., Yun, C.H., Christians, U. & Sewing, K.F. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab. Dispos. 20, 753-761 (1992).
46. Paine, M.F., Leung, L.Y. & Watkins, P.B. New insights into drug absorption: studies with sirolimus. Ther. Drug Monit. 26, 463-467 (2004).
47. Deters, M., Kirchner, G., Resch, K. & Kaever, V. Simultaneous quantification of sirolimus, everolimus, tacrolimus and cyclosporine by liquid chromatography-mass spectrometry (LC-MS). Clin. Chem. Lab. Med. 40, 285-292 (2002).
48. Taylor, P.J., Jones, A., Balderson, G.A., Lynch, S.V., Norris, R.L. & Pond, S.M. Sensitive, specific quantitative analysis of tacrolimus (FK506) in blood by liquid chromatography-electrospray tandem mass spectrometry. Clin. Chem. 42, 279-285 (1996).
49. King, B.P., Leathart, J.B., Mutch, E., Williams, F.M. & Daly, A.K. CYP3A5 phenotype-genotype correlations in a British population. Br. J. Clin. Pharmacol. 55, 625-629 (2003).
50. Cascorbi, I. et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin. Pharmacol. Ther. 69, 169-174 (2001).
51. Haenisch, S. et al. Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex. Pharmacogenomics J. (2006).